

Patient Information	Patient Name: _____ DOB: _____ SSN: _____		
	Address: _____		City: _____ State: _____ Zip: _____
	Phone: _____	Alt Phone: _____	Alternate Contact Info: _____
	Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female Allergies: _____ E-Mail: _____		
	PATIENT CONSENT (Patient, please initial)		
By initialing in the space provided, you are agreeing to receive text messages sent by Premier Pharmacy Services' via automated technology to the mobile phone number provided. Message and data rates may apply. You may text STOP to 97595 to opt-out (you will be sent a confirmation message) or call 800-540-4700 x625			_____ Initial

PLEASE ATTACH COPIES OF FRONT AND BACK OF PATIENT'S PRESCRIPTION INSURANCE CARDS

Clinical	LABS	DIAGNOSIS																
	<table border="1" style="width:100%; border-collapse: collapse;"> <tr><td style="width: 50%;">Serum Calcium:</td><td style="width: 50%;"></td></tr> <tr><td>Date:</td><td></td></tr> <tr><td>Serum Phosphorus:</td><td></td></tr> <tr><td>Date:</td><td></td></tr> <tr><td>25-Hydroxyvitamin D:</td><td></td></tr> <tr><td>Date:</td><td></td></tr> <tr><td>Intact Parathyroid Hormone:</td><td></td></tr> <tr><td>Date:</td><td></td></tr> </table>	Serum Calcium:		Date:		Serum Phosphorus:		Date:		25-Hydroxyvitamin D:		Date:		Intact Parathyroid Hormone:		Date:		Date of Diagnosis: _____ CKD Stage: _____ <input type="checkbox"/> N25.81 Secondary hyperparathyroidism in adults w/stage 3 or 4 CKD and serum total 25-hydroxyvitamin D levels <30ng/ml. <input type="checkbox"/> N25.81 Secondary hyperparathyroidism in adults w/ CKD on dialysis <input type="checkbox"/> N18.6 End stage renal disease <input type="checkbox"/> N25.0 Renal osteodystrophy <input type="checkbox"/> E83.3 Disorders of phosphorus metabolism and phosphatases <input type="checkbox"/> E83.30 Disorder of phosphorus metabolism, unspecified <input type="checkbox"/> E83.39 Other disorders of phosphorus metabolism <input type="checkbox"/> E21.3 Hypercalcemia in adult patients with parathyroid carcinoma <input type="checkbox"/> E21.0 Primary hyperparathyroidism <input type="checkbox"/> E86.1 Euvolemic hyponatremia including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH) <input type="checkbox"/> E87.1 Hypervolemic hyponatremia including patients with heart failure and syndrome of inappropriate antidiuretic hormone (SIADH) <input type="checkbox"/> Other: _____
	Serum Calcium:																	
	Date:																	
	Serum Phosphorus:																	
	Date:																	
	25-Hydroxyvitamin D:																	
Date:																		
Intact Parathyroid Hormone:																		
Date:																		

TRIED AND FAILED HISTORY				
Previous therapy:	<input type="checkbox"/> Sevelamer carbonate	<input type="checkbox"/> Calcium acetate capsules	<input type="checkbox"/> Velphoro	<input type="checkbox"/> Sevelamer hydrochloride
	<input type="checkbox"/> Calcium acetate oral solution	<input type="checkbox"/> Lanthanum carbonate	<input type="checkbox"/> Ferric citrate	<input type="checkbox"/> Other: _____
Duration: _____	Response:	<input type="checkbox"/> Intolerant <input type="checkbox"/> Ineffective <input type="checkbox"/> Contraindicated <input type="checkbox"/> Side Effects: _____ <input type="checkbox"/> Other response: _____		

	MEDICATION	DIRECTIONS	QTY	REFILLS
Prescription	<input type="checkbox"/> Rayaldee ER 30mcg capsules (calcifediol)	<input type="checkbox"/> Take 1 capsule (30mcg) by mouth every day at bedtime <i>(serum calcium should be below 9.8mg/dL before initiating treatment)</i> <input type="checkbox"/> Take 2 capsules (60mcg) by mouth daily after 3 months if intact PTH is above the treatment goal <i>(ensure serum calcium is below 9.8mg/dL, phosphorus is below 5.5mg/dL, and 25-hydroxyvitamin D is below 100ng/mL before increasing dose)</i>	30 caps	_____
	<input type="checkbox"/> Velphoro 500mg chewable tablets (sucroferric oxyhydroxide)	<input type="checkbox"/> Chew or crush 1 tablet by mouth three times daily with meals	90 tabs	_____
	<input type="checkbox"/> Renvela 800mg tablet <input type="checkbox"/> Renvela packet 0.8g <input type="checkbox"/> Renvela packet 2.4g (sevelamer carbonate)	If Serum Phosphorus is >5.5 and <7.5mg/dL: <input type="checkbox"/> Take 0.8g by mouth three times daily with meals If Serum Phosphorus is ≥7.5mg/dL: <input type="checkbox"/> Take 1.6g by mouth three times daily with meals Titration dose: _____ <i>(Prescriber, please indicate titration directions)</i> Titration dosing guide: Titrate by 800mg/dose in 2 week intervals (max daily dose in CKD patients on dialysis = 14g)	30 days supply	_____

	MEDICATION	DIRECTIONS	QTY	REFILLS
Prescription	<input type="checkbox"/> Sevelamer hydrochloride 800mg tablet	If Serum Phosphorus is >5.5 and <7.5mg/dL: <input type="checkbox"/> Take 1 tablet by mouth three times daily with meals If Serum Phosphorus is ≥7.5 and <9.0mg/dL: <input type="checkbox"/> Take 2 tablets by mouth three times daily with meals If Serum Phosphorus is ≥9.0mg/dL: <input type="checkbox"/> Take 2 tablets by mouth three times daily with meals Titration dose: _____ <i>(Prescriber, please indicate titration directions)</i> Titration dosing guide: Titrate by 1 tablet per meal in 2 week intervals to target serum phosphorus levels 3.5-5.5mg/dL (max daily dose = 15g)	90 tabs 180 tabs 180 tabs 30 days supply	_____ _____ _____ _____
	<input type="checkbox"/> Sevelamer hydrochloride 400mg tablet	If Serum Phosphorus is >5.5 and <7.5mg/dL: <input type="checkbox"/> Take 2 tablets by mouth three times daily with meals If Serum Phosphorus is ≥7.5 and <9.0mg/dL: <input type="checkbox"/> Take 3 tablets by mouth three times daily with meals If Serum Phosphorus is ≥9.0mg/dL: <input type="checkbox"/> Take 4 tablets by mouth three times daily with meals Titration dose: _____ <i>(Prescriber, please indicate titration directions)</i> Titration dosing guide: Titrate by 1 tablet per meal in 2 week intervals to target serum phosphorus levels 3.5-5.5mg/dL (max daily dose = 15g)	180 tabs 270 tabs 360 tabs 30 days supply	_____ _____ _____ _____
	<input type="checkbox"/> Sensipar tablet <input type="checkbox"/> <i>Generic cinacalcet hydrochloride</i> <input type="checkbox"/> 30mg <input type="checkbox"/> 60mg <input type="checkbox"/> 90mg	<input type="checkbox"/> Take 1 tablet by mouth every day <input type="checkbox"/> Take 1 tablet by mouth twice a day <input type="checkbox"/> Other: _____	30 tabs 60 tabs	_____ _____ _____
	<input type="checkbox"/> Samsca tablet <input type="checkbox"/> <i>Generic tolvaptan</i> <input type="checkbox"/> 15mg <input type="checkbox"/> 30mg	<input type="checkbox"/> Take 1 tablet by mouth every day <input type="checkbox"/> Other: _____	30 tabs	_____ _____
	<input type="checkbox"/> Other: _____	Directions: _____		_____ _____

PRIOR AUTHORIZATION	
Prescriber Name: _____	NPI: _____ DEA: _____ LIC#: _____
Address: _____	
City: _____ Zip: _____ Tel: _____ Fax: _____	
Contact Person: _____ E-Mail: _____	
PRESCRIBER SIGNATURE	
<small>(Prescriber, please sign and date below)</small>	<small>No stamps. Signature and date must be completed in prescriber's handwriting. NY prescriptions must be submitted via e-script.</small>
I authorize Premier Pharmacy and its representatives to act as an agent to initiate and execute prior authorization for the above patient in order to expedite the process, please provide chart notes and most recent labs.	
Physician's Signature: _____ <input type="checkbox"/> Dispense as written (DAW) Date: ____/____/____	
<small>IMPORTANT NOTICE: This communication is intended for the use of the individual or entity to which it is addressed and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this communication is not the intended recipient or the employee or agent responsible for delivery of the communication, you are hereby notified that any dissemination, distribution, or copying of the communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone.</small>	